| |
Deciphera's kinase switch inhibitors
Distinguishing features
Controlling kinase shape- Switch inhibitors control kinase activity by regulating protein shape, mimicking how cellular kinases are naturally controlled.
New therapies in cancer- Oncogenic (cancer-causing) kinases are often mutated, such that control of kinase shape and activity is lost. Deciphera's approach restores control to such dysregulated kinases.
Solving the problems of drug resistance- Switch inhibitors retain potency against drug-resistant kinase mutations, including mutations in the gatekeeper region.
Control of kinase inhibitor selectivity profiles- Switch inhibitor strategies enable unprecedented selectivity profiles relative to other kinase inhibitor classes.
Switch inhibition of kinases is general- Deciphera has identified kinase switch inhibitors from all major kinase families, including kinases involved in metabolic diseases, inflammation, and cardiovascular deseases.
|
|
Development Programs
DCC-2036
Late-stage preclinical development
Phase 1 trials in CML scheduled for Q1 2009.
» Inhibitor of BCR-ABL and T315I BCR-ABL gatekeeper mutant, resistant to all marketed kinase inhibitors.
DCC-2157
Preclinical development
» Inhibitor of BCR-ABL and T315I BCR-ABL gatekeeper mutant, resistant to all marketed kinase inhibitors.
DP-3407/DP-3429
» Inhibitor primary mutant cKIT kinase and major secondary mutant forms including V654A, D816V, D816H, T670I
Discovery Programs
DP-3346
» Inhibitor of all RAF kinase isoforms, including V600E oncogenic mutant
DP-3590
» Inhibitor of cMET kinase
|
|
In the News
Deciphera Pharmaceuticals LLC (Lawrence, KS USA) announces the initiation of their IND Phase 1 trial for DCC-2036 on March 25, 2009, at MD Anderson Cancer Center in Houston. This Phase 1 study will evaluate the safety and tolerability of once a day continuous oral dosing of DCC-2036, a BCR-ABL kinase inhibitor, in patients with treatment resistant or intolerant Philadelphia chromosome positive chronic myeloid leukemia (CML) or Acute Lymphoblastic Leukemia (ALL) including patients with the T315I gatekeeper amino acid mutation, for whom there remains a significant unmet medical need.
Eli Lilly and Company (NYSE:LLY) and privately-held Deciphera Pharmaceuticals, LLC today announced that the two companies have entered into a collaboration and worldwide licensing agreement related to Deciphera's preclinical B-Raf kinase inhibitor program.
|
